Compare Amgen, Inc. (AMGN) vs iShares MSCI Singapore ETF (EWS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs iShares MSCI Singapore ETF — how do they compare? Amgen, Inc. trades at $416.99 (market cap $224.14B), while iShares MSCI Singapore ETF trades at $33.68. The key difference: Amgen, Inc. pays a 2.43% dividend while iShares MSCI Singapore ETF pays none. Which is the better fit depends on your goals.
| AMGN | EWS | |
|---|---|---|
Market Cap | $224.14B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $417.20 | $33.92 |
52-Week Low | $271.18 | $26.71 |
Enterprise Value | $267.45B | — |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $417.44, up 0.06% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 results, beating EPS estimates and raising full-year guidance, driven by robust product growth. Revenue reached $36.75B in 2025 with a net income margin of 22.95%, though high debt levels remain a focus.
Outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and a data breach investigation. Analyst consensus is Buy with a $394.69 price target, suggesting near-term consolidation after recent gains. The stock's valuation multiples are elevated relative to historical levels.
EWS (iShares MSCI Singapore ETF) trades at $33.66, up 1.48% today and hitting a new 52-week high. Technical indicators show a bullish moving average consensus but overbought RSI signals. The ETF benefits from Singapore's economic resilience and AI-driven growth momentum, with institutional buying from firms like Amundi. Dividend yield remains attractive at 3.97% with consistent payout history.
Outlook remains positive given Singapore's market reforms and AI infrastructure growth, though concentrated financial sector exposure (54%) poses sector-specific risks. Near-term resistance at $34 may challenge further upside without fundamental catalysts. The ETF offers strategic Asian diversification but requires monitoring of regional economic developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About iShares MSCI Singapore ETF
EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.
Read more on EWS →
